Durable relapse-free survival at five years1,2
TAFINLAR (dabrafenib) in combination with MEKINIST (trametinib) is indicated in adults for the adjuvant treatment of Stage III BRAF V600-positive melanoma, following complete resection.3,4
Landmark data demonstrate that the combination of TAFINLAR + MEKINIST offers patients a chance for DURABLE relapse-free survival at five years1,2
Please select an option below to find out more about the efficacy and safety profile of TAFINLAR + MEKINIST from the Phase III COMBI-AD clinical trial, or to discover more about patient management.
- Long GV, et al. N Engl J Med 2017;377:1813–1823.
- Dummer R, et al. N Engl J Med 2020;DOI:10.1056/NEJMoa2005493.
- TAFINLAR (dabrafenib) Summary of Product Characteristics.
- MEKINIST (trametinib) Summary of Product Characteristics.